Christina Ohnsman

Company: Tern Therapeutics

Job title: Chief Medical Officer

Seminars:

Accelerating Progression of TTX-381 through the Value Chain to Address Blindness in CLN2 Batten Disease 10:00 am

Discussing the need for rapid development of Tern Therapeutics TTX-381 to preserve vision in patients with CLN2 Disease Highlighting the steps taken to maximize speed of development, including novel preclinical, clinical, regulatory, and CMC approaches Evaluating implications for rapid development of gene therapies for other rare ophthalmic diseasesRead more

day: Conference Day Two